ATE155690T1 - Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene - Google Patents

Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene

Info

Publication number
ATE155690T1
ATE155690T1 AT92106281T AT92106281T ATE155690T1 AT E155690 T1 ATE155690 T1 AT E155690T1 AT 92106281 T AT92106281 T AT 92106281T AT 92106281 T AT92106281 T AT 92106281T AT E155690 T1 ATE155690 T1 AT E155690T1
Authority
AT
Austria
Prior art keywords
strains
enteric pathogens
negative enteric
vaccine against
against gram
Prior art date
Application number
AT92106281T
Other languages
English (en)
Inventor
Jean-Francois Viret
Stanly J Cryz Jr
Didier Favre
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Application granted granted Critical
Publication of ATE155690T1 publication Critical patent/ATE155690T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/107Vibrio
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0283Shigella
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25Shigella (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92106281T 1992-04-10 1992-04-10 Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene ATE155690T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG1996001047A SG46987A1 (en) 1992-04-10 1992-04-10 Recombinant live vaccines
EP92106281A EP0564689B1 (de) 1992-04-10 1992-04-10 Rekombinanter lebender Impfstoff gegen Gram-negative enterische Pathogene

Publications (1)

Publication Number Publication Date
ATE155690T1 true ATE155690T1 (de) 1997-08-15

Family

ID=26130874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92106281T ATE155690T1 (de) 1992-04-10 1992-04-10 Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene

Country Status (7)

Country Link
EP (1) EP0564689B1 (de)
AT (1) ATE155690T1 (de)
DE (2) DE564689T1 (de)
DK (1) DK0564689T3 (de)
ES (1) ES2083343T3 (de)
GR (1) GR3024848T3 (de)
SG (1) SG46987A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019482A1 (en) * 1993-02-22 1994-09-01 The General Hospital Corporation Heterologous antigens in live cell vaccine strains
BR9609882A (pt) * 1995-08-04 1999-07-27 Univ Guelph Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
GR950300072T1 (en) * 1995-10-13 1996-01-31 Schweiz Serum & Impfinst Recombinant live vaccines against Gram-negative enteric pathogens
AU7410798A (en) * 1996-11-29 1998-06-22 General Hospital Corporation, The Heterologous antigens in live cell V
US6399074B1 (en) 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
WO2001034190A2 (en) * 1999-11-10 2001-05-17 National Research Council Of Canada Live bacterial vaccines against escherichia coli o157:h7
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856935A (en) * 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
EP0250614A1 (de) * 1986-06-23 1988-01-07 Serum Und Impfinstitut Und Institut Zur Erforschung Der Infektionskrankheiten Schweiz. Chromosomale Nukleotid-DNS-Fragmente, die für Zuckersynthetasen und Glukosyltransferasen kodieren
EP0377711A1 (de) * 1988-06-20 1990-07-18 Luminis Pty. Limited Dns-sonden für serotypierung
AR242989A1 (es) * 1988-07-15 1993-06-30 Inst Pasteur I Nat De La Sante Metodo para modificar una cepa salvaje de una shigella entero-invasora para producir una cepa modificada apta para preparar una vacuna contra la cepa salvaje y cepa de shigella asi modificada.
WO1991018092A1 (en) * 1990-05-23 1991-11-28 University Of Maryland At Baltimore Acid-tolerant salmonella typhi, double aro mutants thereof and use as an oral vaccine for typhoid fever

Also Published As

Publication number Publication date
EP0564689B1 (de) 1997-07-23
DK0564689T3 (da) 1998-02-16
ES2083343T3 (es) 1997-12-01
ES2083343T1 (es) 1996-04-16
GR3024848T3 (en) 1998-01-30
SG46987A1 (en) 1998-03-20
DE69221120T2 (de) 1998-02-26
DE564689T1 (de) 1996-06-27
DE69221120D1 (de) 1997-08-28
EP0564689A1 (de) 1993-10-13

Similar Documents

Publication Publication Date Title
DE69713408D1 (de) Streptococcus equi Impstoff
DE69221120D1 (de) Rekombinanter lebender Impfstoff gegen Gram-negative enterische Pathogene
DK0639640T3 (da) Fjerkrævaccine indeholdende smitsomt bronchitis-virus serotype 4/91
DK1047784T3 (da) Neissera meningitidis-antigener
ATE167061T1 (de) Kreuzschützende salmonella impfstoffe
Wolfe et al. The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity
HUP9900919A2 (hu) 2,5-D-Mannóz-csoportot tartalmazó B antigén csoportba tartozó II és III típusú streptococcus poliszacharid-fragmentumok és ezeket tartalmazó vakcinakonjugátumok
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
Confer et al. Serum antibody responses of cattle to iron-regulated outer membrane proteins of Pasteurella haemolytica A1
PT650733E (pt) Vacina in ovo viva atenuada
DE69419966D1 (de) Impstoff gegen Streptococcus suis-Infektion
ATE173166T1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
DE60325696D1 (de) Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
HUP0302612A2 (hu) Salmonella vakcina
ATE263832T1 (de) Lebend-impfstoffe gegen gram-negative pathogene, die heterologe o-antigene exprimieren
ATE392429T1 (de) Lebend-impfstoff gegen heliobacter pylori
Sippel et al. Homogeneity of protein serotype antigens in Neisseria meningitidis group A
DE60042489D1 (de) Impfstoff gegen neisseria infektion
NZ295877A (en) A vaccine comprising the helicobacter bacterium and its use
Sibalin Cross-neutralization tests with swine enterovirus strain S 180/4, and Teschen, Talfan, and swine polio-encephalomyelitis viruses
DE3750549D1 (de) Impfstoff gegen schweinedysenterie.
NO931655L (no) Syntetiske lipid a glykokonjugatantigener for anvendelse i vaksiner
DE69208854D1 (de) Impfstoff-Zubereitung zur Vorbeugung gegen bei Tieren durch Chlamydia psitacci verursachte Fehlgeburt
WO2024025936A3 (en) Development of carbohydrate-based anti-salmonella vaccines
SE8605303D0 (sv) Anordning vid bildror

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee